Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Merck & Company (MRK)

Merck & Company (MRK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Pharma ETFs Soar on Robust Q2 Earnings

Total earnings of 66.4% of the healthcare market capitalization that has reported so far are up 4.4% on revenue growth of 4%.

JNJ : 148.60 (+0.71%)
PFE : 38.45 (+0.47%)
MRK : 81.02 (-0.04%)
LLY : 152.93 (+0.03%)
BMY : 61.02 (-0.51%)
PPH : 63.76 (-0.93%)
PJP : 66.72 (+0.09%)
IHE : 163.81 (+0.43%)
XPH : 44.73 (+0.58%)
FTXH : 24.46 (+0.25%)
Nektar's (NKTR) Q2 Earnings Beat, Bempeg Makes Progress

Nektar (NKTR) reports encouraging second-quarter 2020 results. The company continues to progress with its pipeline candidates.

PFE : 38.45 (+0.47%)
MRK : 81.02 (-0.04%)
BMY : 61.02 (-0.51%)
NKTR : 21.85 (+1.58%)
Pharma Stock Roundup: ABBV, MRK Q2 Earnings & Coronavirus Updates in Focus

Sanofi (SNY)/Glaxo (GSK) and J&J (JNJ) sign deals with U.S. government for coronavirus vaccine candidate. Several drugmakers announce second-quarter results.

JNJ : 148.60 (+0.71%)
SNY : 51.51 (+0.02%)
MRK : 81.02 (-0.04%)
LLY : 152.93 (+0.03%)
GSK : 40.79 (-0.44%)
ABBV : 92.92 (+0.38%)
Exelixis' (EXEL) Q2 Earnings and Revenues Surpass Estimates

Exelixis (EXEL) beats on earnings and sales in the second quarter.

RHHBY : 43.0100 (-0.97%)
MRK : 81.02 (-0.04%)
EXEL : 22.36 (-1.97%)
BMY : 61.02 (-0.51%)
Global Vaccines Industry Landscape 2020-2027: Increase in Incidence of Both Viral and Bacterial Infectious Diseases

, /PRNewswire/ -- The report has been added to offering.

CSLLY : 98.4500 (-1.87%)
DSNKY : 88.3150 (+0.89%)
MRK : 81.02 (-0.04%)
MTZPY : 18.6000 (-0.13%)
PFE : 38.45 (+0.47%)
Novo Nordisk's (NVO) Q2 Earnings Beat Estimates, Sales Miss

Novo Nordisk's (NVO) earnings surpass estimates but revenues miss the same in the second quarter of 2020.

NVO : 64.64 (+1.49%)
SNY : 51.51 (+0.02%)
MRK : 81.02 (-0.04%)
LLY : 152.93 (+0.03%)
Moderna (MRNA) Q2 Earnings and Revenues Surpass Estimates

Moderna (MRNA) reports narrower-than-expected second-quarter loss. Shares decline presumably on absence of any new data on coronavirus vaccine candidate.

AZN : 55.41 (-1.42%)
MRK : 81.02 (-0.04%)
MRNA : 74.10 (+0.46%)
VRTX : 272.99 (-0.13%)
Bristol-Myers (BMY) Q2 Earnings Beat, 2020 Earnings View Up

Bristol-Myers (BMY) beats on earnings and sales in the second quarter on the strength of Revlimid and Eliquis.

PFE : 38.45 (+0.47%)
MRK : 81.02 (-0.04%)
BMY : 61.02 (-0.51%)
XLRN : 99.12 (-6.89%)
Colorectal Cancer Drugs Market Research Report by Class - Global Forecast to 2025 - Cumulative Impact of COVID-19

, /PRNewswire/ --Read the full report: The Global Colorectal Cancer Drugs Market is expected to grow from in 2019 to by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 3.94%.Market Segmentation...

ABBV : 92.92 (+0.38%)
AMGN : 240.69 (-0.36%)
ALPMF : 15.7550 (-0.41%)
LLY : 152.93 (+0.03%)
MRK : 81.02 (-0.04%)
NVS : 82.91 (-0.60%)
PFE : 38.45 (+0.47%)
Global PD-L1 NSCLC Market: Insights, Epidemiology, Drugs and Players (2017-2030)

, /PRNewswire/ -- The drug pipelines has been added to offering.

BMY : 61.02 (-0.51%)
GSK : 40.79 (-0.44%)
MRK : 81.02 (-0.04%)
MKKGY : 26.7200 (-0.48%)
NVS : 82.91 (-0.60%)
REGN : 620.21 (-0.16%)
Cocrystal Pharma Reports Second Quarter 2020 Financial Results and Provides Updates on Antiviral Programs

- COVID-19 program in preclinical development; Discussions with potential strategic partners ongoing -

MRK : 81.02 (-0.04%)
COCP : 2.04 (-1.92%)
Corcept (CORT) Q2 Earnings Top Estimates, Revenues Miss Mark

Corcept's (CORT) earnings trump estimates for the second quarter of 2020 while revenues fall shy of the same.

MRK : 81.02 (-0.04%)
BMY : 61.02 (-0.51%)
BLRX : 2.15 (+12.57%)
CORT : 13.94 (-0.21%)
Epizyme's (EPZM) Q2 Earnings and Revenues Miss Estimates

Epizyme (EPZM) reports a wider-than-expected loss and misses sales estimates in the second quarter of 2020.

PFE : 38.45 (+0.47%)
MRK : 81.02 (-0.04%)
NVS : 82.91 (-0.60%)
EPZM : 12.87 (+0.31%)
Life Sciences Industry Leader Brian Kim Joins Summit Partners as Executive-in-Residence

Global growth equity investor Summit Partners today announced the addition of Brian Kim to the firm's Executive-in-Residence ("EIR") program. In this role, Mr. Kim will work closely with Summit's healthcare...

MRK : 81.02 (-0.04%)
PKI : 119.33 (+0.24%)
Merck Animal Health Completes Acquisition of IdentiGEN

Merck Animal Health, known as MSD Animal Health outside the United States and Canada, a division of Merck & Co., Inc., Kenilworth, N.J., USA (NYSE:MRK), today announced the completion of its acquisition...

MRK : 81.02 (-0.04%)
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Market 2020 with COVID-19 Impact Analysis

report by Marketinsightsreports offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Clostridium Difficile Infections (Clostridium Difficile...

IMRN : 10.97 (-1.53%)
MRK : 81.02 (-0.04%)
NVS : 82.91 (-0.60%)
VRX.TO : 30.80 (-3.33%)
3 Diverse Large-Cap Stocks to Buy Now to Boost Your Long-Term Portfolio

Investors should consider adding a few large-cap names that are prepared to grow for years to come. These three stocks also pay dividends and provide exposure to three very different and vital industries......

NOC : 329.27 (+0.90%)
MSFT : 212.48 (-1.79%)
BA : 170.02 (-1.27%)
AAPL : 444.45 (-2.45%)
PFE : 38.45 (+0.47%)
MRK : 81.02 (-0.04%)
AMD : 84.85 (-2.15%)
LLY : 152.93 (+0.03%)
LMT : 385.62 (+1.55%)
NFLX : 494.73 (-2.82%)
ABBV : 92.92 (+0.38%)
SPOT : 252.12 (-1.25%)
ZM : 258.73 (-3.55%)
5 Growth ETFs & Stocks to Ride the Market Rally

Growth investing has taken the lead over value and is likely to stay given a slew of reasons.

JNJ : 148.60 (+0.71%)
PFE : 38.45 (+0.47%)
MRK : 81.02 (-0.04%)
MRNA : 74.10 (+0.46%)
LLY : 152.93 (+0.03%)
QDEL : 272.76 (-4.41%)
NLS : 12.01 (+7.71%)
INO : 20.22 (-0.54%)
SHOP : 1,053.12 (-3.22%)
VUG : 222.16 (-0.90%)
JKE : 257.02 (-1.27%)
MGK : 180.47 (-0.93%)
IWY : 117.80 (-1.04%)
VERI : 12.98 (+1.64%)
JKH : 316.88 (-1.05%)
Will Eliquis, Revlimid Drive Bristol-Myers (BMY) Q2 Earnings?

Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports second-quarter 2020 results.

RHHBY : 43.0100 (-0.97%)
BMRN : 118.67 (-0.82%)
MRK : 81.02 (-0.04%)
BMY : 61.02 (-0.51%)
Merck and Hanmi Pharmaceutical Enter into Licensing Agreement to Develop Efinopegdutide, an Investigational Once-Weekly Therapy for Nonalcoholic Steatohepatitis (NASH)

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Hanmi Pharmaceutical today announced that the companies have entered into an exclusive licensing agreement for the development,...

MRK : 81.02 (-0.04%)

Van Meerten Stock Picks

The 5 Best MidCaps
I wanted to find the 5 Mid Caps that have had the best momentum over the past year so I used Barchart to sort the S&P 400 MidCap Stock Index for the stocks with the highest Weighted Alpha and technical buying signals.
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar